文献速递乳房整形与再造显微修复重建

加速康复外科路径对显微乳房再造化疗患者的影响

Implications of Instituting an Enhanced Recovery after Surgery Pathway in Patients Receiving Chemotherapy in Microsurgical Breast Reconstruction.
PubMed 文献 · Plast Reconstr Surg · 2021-01-01

该回顾性研究纳入256例接受深 inferior epigastric perforator 皮瓣乳房再造的患者,其中113例有化疗暴露史,比较加速康复外科(ERAS)实施前后阿片类药物消耗量。结果显示,ERAS前化疗暴露者阿片消耗显著更高(278.5 mg vs 211.5 mg,p=0.0279),ERAS后两组无差异(137.4 mg vs 133.0 mg,p=0.7251)。

要点

  • 化疗暴露患者在ERAS前需要更多阿片类药物才能达到舒适。
  • 实施ERAS路径后,化疗暴露与未暴露者的阿片消耗无显著差异。
  • 需进一步研究化疗暴露患者术后疼痛管理更优方案。

核心结论

  • 化疗暴露患者需要更多阿片类药物才能舒适;ERAS路径可消除化疗史相关的阿片消耗差异。

研究设计与样本

  • 回顾性综述,纳入2016年1月至2019年9月由两位资深作者完成的深 inferior epigastric perforator 皮瓣乳房再造患者256例,分为ERAS前和ERAS后两组,主要结局为术后阿片消耗量(口服吗啡当量)。

主要发现

  • ERAS前组中,无化疗暴露者阿片消耗211.5 mg,有化疗暴露者278.5 mg,差异有统计学意义(p=0.0279)。
  • ERAS后组中,无化疗暴露者阿片消耗137.4 mg,有化疗暴露者133.0 mg,差异无统计学意义(p=0.7251)。

临床怎么用

  • 对接受显微乳房再造的化疗暴露患者,实施ERAS路径可能有助于减少术后阿片类药物需求。

局限性

  • 尚不清楚化疗暴露患者阿片需求增加是源于疼痛增加还是阿片疗效降低。
  • 需进一步研究评估化疗暴露患者术后疼痛管理的更好方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neuropathy is a common side effect of chemotherapeutic agents. Manifestations of chemotherapy-induced neuropathy can present in a myriad of fashions, ranging from numbness, tingling, and pain to motor weakness and autonomic dysfunction.1 Given the nature of breast reconstruction, a significant portion of the patients have a history of chemotherapy exposure; its effect on postoperative pain management has not been previously explored. METHODS: This study is a retrospective review of patients who underwent deep inferior epigastric perforator flap breast reconstruction performed by the two senior authors from January of 2016 to September of 2019. The patients were separated into two groups, before and after enhanced recovery after surgery. The primary outcome observed was postoperative opioid consumption, measured as oral morphine equivalents; p values were obtained through univariate linear regression. RESULTS: In total, 256 patients were analyzed, of which 113 had chemotherapy exposure. The difference between opioid consumption in patients in the pre-enhanced recovery after surgery group without and with chemotherapy exposure was statistically significant (211.5 mg versus 278.5 mg; p = 0.0279). There was no difference between opioid consumption with regard to chemotherapy history in the enhanced recovery after surgery group (137.4 mg versus 133.0 mg; p = 0.7251). CONCLUSIONS: Patients with chemotherapy exposure required more opioids to be comfortable. It is unknown whether this difference is secondary to increased pain or less effectiveness of opioids. Further research is necessary to assess whether there are better ways to address pain postoperatively in patients with chemotherapy exposure. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Haddock NT, Garza R, Boyle CE, et al. Implications of Instituting an Enhanced Recovery after Surgery Pathway in Patients Receiving Chemotherapy in Microsurgical Breast Reconstruction. Plast Reconstr Surg. 2021. PMID: 33002977. doi:10.1097/PRS.0000000000007418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。